You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Campath-1H Monoclonal Antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)

Recruiting
  • Sickle Cell Disease
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jul 31, 2022

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
Has Results
  • Stage I Chronic Lymphocytic Leukemia
  • +3 more
  • alemtuzumab
  • +2 more
  • Chicago, Illinois
  • +1 more
Dec 29, 2020

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

Recruiting
  • Acute Gout
  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
  • +6 more
  • Wuhan, Hubei, China
  • +2 more
Oct 17, 2022

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia Trial in

Completed
Has Results
  • B-cell Chronic Lymphocytic Leukemia
  • +4 more
  • alemtuzumab
  • +9 more
  • Rochester, Minnesota
    Mayo Clinic
Jun 11, 2020

COVID-19 Trial in Joondalup (VYD222, Placebo)

Recruiting
  • COVID-19
  • Joondalup, Western Australia, Australia
    Linear Clinical Research
Apr 3, 2023

Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans Trial in Minsk, Riga (Monoclonal antibody (Mab) sB24M)

Active, not recruiting
  • Pyoderma
  • +3 more
  • Monoclonal antibody (Mab) sB24M
  • Minsk, Belarus
  • +1 more
Jul 8, 2022

Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

Recruiting
  • Non-Malignant Neoplasm
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 29, 2022

Solid Tumor Trial (GS-4528, Zimberelimab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Apr 21, 2023

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

Efficacy of PD-1 Monoclonal Antibody

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • PD-1 Inhibitor
    • Guangzhou, China
      Nanfang Hospital
    Jul 5, 2022

    Aplastic Anemia Trial run by the NHLBI (Campath-1H, r-ATG, CsA)

    Completed
    Has Results
    • Aplastic Anemia
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Jul 2, 2021

    Allergic Rhinitis Trial in Wuhan (GR1802 injection-1, GR1802 injection-2, Placebo)

    Recruiting
    • Allergic Rhinitis
    • GR1802 injection-1
    • +2 more
    • Wuhan, Hubei, China
      Tongji Hosptial affiliated to Tongji Medical college of Huazhong
    Sep 7, 2023

    LAD1 Trial run by the NIAID (Ustekinumab)

    Recruiting
    • LAD1
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 24, 2023

    Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)

    Enrolling by invitation
    • Malignant Melanomas
    • Recombinant Human Adenovirus Type 5 Injection
    • Fuzhou, Fujian, China
      Fujian Cancer Hospital, Department of Internal Medicine, Ward 19
    Jul 7, 2023

    Thyroid Eye Disease Trial (VRDN-001 10 mg/kg Drug:)

    Not yet recruiting
    • Thyroid Eye Disease
    • VRDN-001 10 mg/kg Drug:
    • (no location specified)
    Sep 7, 2023